As far as I know, no apabetalone clinical trials are ongoing, combined with other existing drugs such as cardio, diabetes or chronic kidney disease, to extend their patent life. This still needs to occur and be proven before anything goes to the market to benefit the RVX shareholders.

The BOM2 (apabetalone in combination with SGLT2 inhibitor) may be the closest trial to prove the worth of apabetalone. Sorry to say, we're not there yet.  

"Based on data from the Phase 3 trial, BETonMACE, apabetalone treatment reduced the hazard of MACE and hospitalization due to heart failure by 63% (p=0.0002), among patients taking next-generation glucose-lowering drugs, in a post-hoc analysis." .............. As we're told this will conclusively be demonstrated in BOM2 Trial.

Koo